about
Endocrine effects of the combination of megestrol acetate and tamoxifen in the treatment of metastatic breast cancerClinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancerCharacterization of the antitumor activity of hexadecylphosphocholine (D 18506)Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVDAmelioration of 4'-epidoxorubicin-induced cardiotoxicity by sodium cromoglycateCombination chemotherapy for primary small intestinal lymphoma in the Middle EastDetection of tumours with nuclear magnetic resonance spectroscopy of plasma.Quality control of validity of data collected in clinical trials. EORTC Study Group on Data Management (SGDM).Phase I study of fludarabine (2-fluoro-ara-AMP).The absence of influence of acetylsalicylic acid (ASA) on the transient decrease in platelet counts observed after infusion of bleomycin and vinblastine.Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma.Effects of antineoplastic treatment of HIV-positive patients with testicular cancer.Phase I clinical trial with carbetimer.Phase II studies of mitozolomide in melanoma, lung and ovarian cancer.A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U).Carboplatin and continuous infusion 5-fluorouracil for advanced head and neck cancer.Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer. EORTC-GU Group protocol 30867.A phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder.Phase II study of tauromustine in disseminated malignant melanoma.Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion.Phase II evaluation of trans-N3P3Az2(NHMe)4 (AZP) in non-small cell lung cancer.High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study.4'-Deoxydoxorubicin, an inactive drug in small cell lung cancer.Teniposide (VM26): an effective treatment for brain metastases of small cell carcinoma of the lung.Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors.Phase II trial of mitoxantrone in patients with hepatocellular carcinoma.A phase II trial of oral idarubicin plus dibromodulcitol in advanced breast cancer.Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days.Etoposide, cisplatin and doxorubicin in patients with small cell lung cancer: tumor response and long term survival.Phase I study of a carboplatin-etoposide combination in advanced thoracic cancer.Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.Phase I study of alpha-difluoromethylornithine and methyl-GAG.Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients.Mitomycin C-induced renal toxicity, a dose-dependent side effect?A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.Phase II study of iproplatin (CHIP, JM-9) in advanced testicular cancers progressing after prior chemotherapy.Therapeutic efficacy of danazol in myelodysplastic syndromes.Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG).
P1433
Q28268429-E1F073EB-E6F4-47FB-9E19-BBEDECB297E6Q28285819-D3868F63-E80B-47C9-8F8C-79848DB8473BQ28291309-4A75DA7D-9C6E-4C24-9581-C172777F394CQ28299706-037DF5A3-4131-498B-BD69-388618651158Q28339599-5398FAC7-3A4D-48D8-B092-7E24CF09D053Q28339947-7A6A3195-3C0F-4202-85C5-A617035A1A59Q31065484-64B1F2EA-8767-46CA-B683-20E40754712EQ31133261-F4236A6A-F5A1-4554-A9A4-14ED7471FE04Q33411095-CE8090F2-E577-4361-9A8B-4DA4F779CEC1Q33411342-7A652F2C-45EA-4FF4-87D0-045E034378E0Q33411838-58FC3C3F-E5A3-44E5-B0FD-FDDA4AAF4AB5Q33414650-7B8AC804-D9CF-4251-BC9A-F30241715F85Q33418683-AEDD8E46-E296-4064-833E-58C49459A12FQ33418992-10A35F6E-B99F-45C7-BC7E-928EC0DDCF0DQ33422345-4F8A36BA-A98C-4395-A158-D78E25EE5A45Q33425542-C87BD5A5-4525-4997-A0F5-7D13A19DA324Q33426980-746FDE3D-EFCE-4EAD-B697-7D1204742CA2Q33430711-35EDDBC2-C7E7-4D94-B3FA-5298461857DDQ33431134-75699EB4-C083-4685-A66D-9CEB3C4D96E2Q33431137-3374AD8E-5F20-49D7-93FF-68E8AF3D6779Q33431958-7D982AAE-F890-4648-92F0-0899D872C64AQ33433592-B870B9EE-3D53-4D40-9CF0-F7B1A682EA98Q33439407-4E7707DF-8D69-456C-9C60-9475393F4640Q33439689-F8160F3D-A5D8-46C1-9FA5-0777FCEF2431Q33439694-44A69D33-24EC-4C71-8C5F-4B77445E0073Q33440734-2174AE90-C3CD-4477-809B-0331AE2F504EQ33440737-ACA9D9B6-ED10-41FD-98F8-FB027985D4ACQ33441930-E00D206A-61CF-4A46-AAFF-AC6B9B580ED7Q33444378-DE1BFE3C-BB88-4861-86A9-481E2E5F45A2Q33444876-7D790F17-F18E-4E55-9318-55461446D8ECQ33445440-261E05DB-9413-4219-BEC0-E65EF5B5633EQ33445754-CB293C6D-1D54-4CB4-8C3D-82554950BFB4Q33445854-0659DC19-E3E6-407D-8F1E-9C5082B6C8A0Q33446244-688392A6-86DB-40B1-9484-9DB8527679BAQ33446386-289F3092-D5C4-4E2A-909D-F779426D75D1Q33447224-F470329B-FF93-48D9-B716-2DF1CAFBDCBCQ33447923-BDD56689-54E0-45F5-AB3C-F3F7049F49CAQ33448165-8C173603-723A-4FC1-A11D-F61AEFB29BF8Q33448169-01E4983E-FB52-4750-8147-0E3278D5C65CQ33449430-2A3398BA-B7F4-45DD-8E42-1F9EF66F12EC
P1433
description
revista científica
@es
revue scientifique
@fr
rivista scientifica
@it
scientific journal
@en
wetenschappelijk tijdschrift van Pergamon Press
@nl
wissenschaftliche Fachzeitschrift
@de
науковий журнал
@uk
name
European Journal of Cancer & Clinical Oncology
@ast
European Journal of Cancer & Clinical Oncology
@de
European Journal of Cancer & Clinical Oncology
@en
European Journal of Cancer & Clinical Oncology
@es
European Journal of Cancer & Clinical Oncology
@fr
European Journal of Cancer & Clinical Oncology
@it
European journal of cancer & clinical oncology
@nl
type
label
European Journal of Cancer & Clinical Oncology
@ast
European Journal of Cancer & Clinical Oncology
@de
European Journal of Cancer & Clinical Oncology
@en
European Journal of Cancer & Clinical Oncology
@es
European Journal of Cancer & Clinical Oncology
@fr
European Journal of Cancer & Clinical Oncology
@it
European journal of cancer & clinical oncology
@nl
altLabel
Eur J Cancer Clin Oncol
@en
prefLabel
European Journal of Cancer & Clinical Oncology
@ast
European Journal of Cancer & Clinical Oncology
@de
European Journal of Cancer & Clinical Oncology
@en
European Journal of Cancer & Clinical Oncology
@es
European Journal of Cancer & Clinical Oncology
@fr
European Journal of Cancer & Clinical Oncology
@it
European journal of cancer & clinical oncology
@nl
P3181
P1055
P1156
9500153952
P123
P1476
European Journal of Cancer & Clinical Oncology
@en